Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FALMINA vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the synaptic cleft, leading to increased serotonin levels.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Major depressive disorder,Obsessive-compulsive disorder,Panic disorder,Bulimia nervosa,Premenstrual dysphoric disorder
Prevention of pregnancy
FALMINA (fictitious drug): 500 mg orally every 12 hours.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
Terminal elimination half-life 12-15 hours; in severe renal impairment (Cr Cl <30 m L/min) extends to 30-40 hours, requiring dose adjustment.
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Hepatic via CYP2D6; active metabolite norfluoxetine; elimination half-life 4-6 days (fluoxetine), 4-16 days (norfluoxetine).
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Primarily renal (85% unchanged drug, 10% as glucuronide conjugate); biliary/fecal 5%.
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
98% bound to albumin.
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
0.2-0.3 L/kg, reflecting confinement to plasma and interstitial space; minimal tissue penetration.
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Oral: 75-85% due to moderate first-pass metabolism; IV: 100%.
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
GFR 30-59 m L/min: 500 mg every 24 hours. GFR 15-29 m L/min: 250 mg every 24 hours. GFR <15 m L/min: 125 mg every 24 hours. Hemodialysis: 125 mg post-dialysis.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: use with caution; 250 mg every 24 hours.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
5 mg/kg/dose orally every 12 hours; maximum 500 mg/dose.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
Initiate at 250 mg orally every 12 hours; titrate to renal function.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Serotonin syndrome; discontinuation syndrome; hyponatremia; bleeding risk; mania/hypomania; seizures; angle-closure glaucoma; QT prolongation (overdose).
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Concurrent use with MAOIs or within 14 days of MAOI use; concurrent use with pimozide or thioridazine; hypersensitivity to fluoxetine.
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
Avoid high-sodium foods as they can counteract the diuretic effect. Limit licorice intake (glycyrrhizin) which can worsen hypokalemia. Grapefruit juice may increase absorption; avoid large amounts. Maintain adequate fluid intake unless fluid restriction is advised.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
Falmina is a combined oral contraceptive containing ethinylestradiol and drospirenone. Category X: contraindicated in pregnancy. First trimester: no increased risk of major malformations in exposed fetuses based on epidemiological studies, but use is not recommended due to lack of need. Second and third trimesters: associated with increased risk of fetal harm including congenital anomalies (limb defects, heart defects) and adverse outcomes (low birth weight, preterm birth) from continued exposure. Risk of fetal feminization from progestin component in late pregnancy.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Small amounts of ethinylestradiol and drospirenone are excreted in breast milk; M/P ratio not determined. Use may reduce milk production and composition. Avoid use in breastfeeding women, especially during early postpartum period, due to potential for decreased milk supply and presence in milk. Alternative contraception recommended.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
Falmina is contraindicated in pregnancy; no dose adjustments are applicable because use should be discontinued immediately upon pregnancy diagnosis. No pharmacokinetic data guide dosing in pregnancy as it is not indicated.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
FALMINA is a high-ceiling loop diuretic used for edema and hypertension. Monitor serum potassium and magnesium regularly; risk of hypokalemia and hypomagnesemia. Ototoxicity is dose-dependent and more common with rapid IV administration or concurrent use of other ototoxic drugs. Onset of action: oral 30-60 min, IV 5 min. Duration: oral 6-8 hr, IV 2 hr. Avoid in anuria, hepatic coma, severe electrolyte depletion.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take this medication exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Report any hearing loss, ringing in ears, or dizziness immediately, especially if on high doses or other ototoxic drugs.,Weigh yourself daily and notify your doctor if you gain more than 2-3 pounds in 24 hours or lose weight too quickly.,Avoid sudden position changes to prevent dizziness; rise slowly from sitting or lying down.,Limit alcohol intake as it may worsen dizziness and low blood pressure.,This drug may increase blood sugar; monitor glucose if diabetic.,Do not take with NSAIDs (e.g., ibuprofen, aspirin) unless approved by your doctor as they may reduce effectiveness and increase kidney risk.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FALMINA vs ALYACEN 7/7/7, answered by our medical review team.
FALMINA is a Oral Contraceptive that works by Selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the synaptic cleft, leading to increased serotonin levels.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FALMINA and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FALMINA is: FALMINA (fictitious drug): 500 mg orally every 12 hours.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FALMINA and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FALMINA is classified as Category C. Falmina is a combined oral contraceptive containing ethinylestradiol and drospirenone. Category X: contraindicated in pregnancy. First trimester: no increased risk of major malform. ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.